Clinical trials: Breast Cancer/ Metastatic Breast Cancer
Male Breast Cancer, Recurrent Breast Cancer
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving aromatase inhibitor (AI) therapy.
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT01153672
- Testing
- vorinostat, laboratory biomarker analysis, biopsy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Washington
Stage IV Breast Cancer
Vaccination of High Risk Breast Cancer Patients
Objective - Determine the safety and tolerability of a peptide mimotope-based vaccine upon immunization of breast cancer subjects.
- Trial name
- NCT01390064
- Testing
- Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Arkansas
Breast Cancer Metastatic, Breast Carcinoma
Immun Checkpoint Washout in Patients With Invasive Ductal Breast Cancer
Invasive ductal carcinoma is the most common type of invasive breast cancer. In cases where axillary lymph node metastases are diagnosed through screening, they can be found in up to 25% of cases, and in symptomatic cases, up to…
- Trial name
- NCT07003009
- Testing
- Malign Lymph Node Washout, Benign Lymph Node Washout
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Istanbul Training and Research Hospital
Breast Cancer Stage IV, Ovarian Cancer
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
This is a phase II clinical trial of the combination of carboplatin, eribulin, and Veliparib.
- Conditions
- Breast Cancer Stage IV, Ovarian Cancer, BRCA1 Mutation, BRCA2 Mutation
- Trial name
- NCT03032614
- Testing
- Carboplatin, Eribulin, Veliparib
- Sponsor
- The University of Texas Health Science Center at San Antonio
Stage IV (Metastatic) Breast Cancer, Metastatic Breast Cancer
Fulvestrant + Neratinib In Breast Cancer
This is a Phase 2 open label, multi-center non-randomized interventional study designed to evaluate the safety and efficacy of combining Neratinib plus Fulvestrant in previously treated metastatic HR-positive, HER2-negative…
- Conditions
- Stage IV (Metastatic) Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, PR-Positive Breast Cancer
- Trial name
- HER2-Signal (NCT04901299)
- Testing
- NERATINIB, FULVESTRANT
- Where
- 2 sites in United States
- Sponsor
- Massachusetts General Hospital
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
This phase I trial tests the safety, side effects, and best dose of pidnarulex in combination with trastuzumab deruxtecan in treating patients with breast cancer and other solid tumors that express varying levels of a protein…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally Advanced Breast Carcinoma
- Trial name
- NCT07137416
- Testing
- Biopsy Procedure, Biospecimen Collection, Echocardiography Test
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
The purpose of this study is to find out the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDEs) of JNJ-101684362 (HLD-0117), to evaluate the safety of JNJ-101684362 (HLD-0117) , and how well the…
- Trial name
- HLD-0117 (NCT07524855)
- Testing
- JNJ-101684362 (HLD-0117)
- Where
- 6 sites in United States
- Volunteers
- 170 people
- Sponsor
- Janssen Research & Development, LLC
Breast Cancer
E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer
The purpose of this study is to compare Overall Survival (OS), Progression Free Survival (PFS), objective tumor response rate, duration of response, and safety in patients treated with E7389 versus the Treatment of Physician's…
- Trial name
- NCT00388726
- Testing
- E7389, Physician's Choice
- Where
- 137 sites in United States, Argentina and 15 more
- Volunteers
- 762 people
- Sponsor
- Eisai Inc.
Metastatic Breast Cancer
Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP
2X-121 is a small molecule targeted inhibitor of Poly ADP ribose polymerase (PARP), a key enzyme involved in DNA damage repair in cancer cells.
- Trial name
- NCT03562832
- Testing
- PARP inhibitor 2X-121
- Where
- 2 sites in Denmark
- Volunteers
- 20 people
- Sponsor
- Allarity Therapeutics
HER2-positive Breast Cancer, Recurrent Breast Cancer
Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer
This phase II trial studies how well capecitabine, cyclophosphamide, lapatinib ditosylate, and trastuzumab work in treating patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.
- Conditions
- HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT01873833
- Testing
- capecitabine, cyclophosphamide, lapatinib ditosylate
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Southern California
Gynecologic Cancer, Gynecologic Neoplasms
Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis
Background: Tumors that have spread to the lining of the abdomen from other cancers, such as cancer of the appendix, colon, or ovary, are called peritoneal carcinomatosis. In most cases, outcomes are poor.
- Conditions
- Gynecologic Cancer, Gynecologic Neoplasms, Peritoneal Carcinomatosis, Peritoneal Neoplasms
- Trial name
- NCT05185947
- Testing
- Paclitaxel, Nilotinib, ECG
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
This clinical trial is a Phase I dose escalation and dose expansion and Phase II monotherapy open-label, first-in-human, multicenter study of OP-1250 in adult subjects with advanced and/or metastatic hormone receptor…
- Trial name
- NCT04505826
- Testing
- OP-1250
- Where
- 19 sites in United States, Australia
- Volunteers
- 153 people
- Sponsor
- Olema Pharmaceuticals, Inc.
Breast Cancer, Triple Negative Breast Cancer
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
This research study is looking to see whether the combination of Dostarlimab and Niraparib plus Radiation Therapy (RT) is safe and effective in participants with metastatic triple negative breast cancer.
- Trial name
- NADiR (NCT04837209)
- Testing
- Niraparib, Dostarlimab, Radiation therapy
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- Massachusetts General Hospital
Palmar-Plantar Erythrodysesthesia, Breast Cancer
Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome
The purpose of this research study is to see if combining uracil cream (UTC) with capecitabine (Xeloda) can prevent Hand-Foot Syndrome.
- Trial name
- NCT01100463
- Testing
- Cream, 0.1% Uracil Cream
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Nanometics (d.b.a. PHD Biosciences)
Inflammatory Breast Cancer, Stage II Breast Cancer
Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer
Drugs used in chemotherapy, such as doxorubicin and cyclophosphamide, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Inflammatory Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT00049114
- Testing
- doxorubicin hydrochloride, cyclophosphamide, tipifarnib
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Breast Inflammatory Carcinoma, Stage IV Breast Inflammatory Carcinoma
Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
This phase II trial studies how well atezolizumab, cobimetinib, and eribulin work in treating patients with inflammatory breast cancer that has spread to other places in the body (metastatic).
- Trial name
- NCT03202316
- Testing
- Atezolizumab, Cobimetinib, Eribulin
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer Metastatic
HER2-PET: Predicting T-DXd Efficacy and HER2 Heterogeneity
The study will be conducted as an open-label, single-center, Phase II clinical study, with a planned enrollment of 86 patients with locally advanced or metastatic HER2-positive and HER2-low breast cancer who are intended to…
- Trial name
- PREDICT-HER (NCT07586215)
- Testing
- PET
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
Breast Cancer, Surgery
Targeted Resection of Axillary Metastatic Lymph Nodes After Breast Cancer Neoadjuvant Chemotherapy
This study evaluates the efficacy and feasibility of Carbon Nanoparticle Suspension Injection (CNSI) for Targeted Axillary Dissection (TAD) in breast cancer patients undergoing neoadjuvant chemotherapy (NAC), compared to…
- Conditions
- Breast Cancer, Surgery, Lymph Node Metastases
- Trial name
- NCT04744506
- Testing
- Tissue Marker Clip, Carbon Nanoparticle Suspension Injection
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer
Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer
The purpose of this study is to find the highest dose of capecitabine and oral navelbine that can be given without causing severe side effects, and to determine the safety, tolerability, and effects (good and bad) of capecitabine…
- Trial name
- NCT00153907
- Testing
- Navelbine, Capecitabine
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Dana-Farber Cancer Institute
Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma
INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study
This is a phase 2 study to evaluate the safety and efficacy of the combination of INCMGA00012 and pelareorep and to see how well they work in treating patients with triple negative breast cancer that has spread to other parts of…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
- Trial name
- NCT04445844
- Testing
- Pelareorep, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Mridula George, MD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.